An interventional study of NVP-NK4146 and NVP-NK4146 Placebo in Alzheimer Disease, sponsored by NVP Healthcare. Enrolling by invitation at 1 site in South Korea. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-09-01.
Sponsored by NVP Healthcare · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 174 studies in Alzheimer Disease with a site in Korea, Republic of — 34 open to participants now, 46 under way, 16 of them phase 3. Alzheimer Disease · Korea, Republic of.
Among the 174 studies in Alzheimer Disease with a site in Korea, Republic of, this one is the 119th largest by planned enrollment of the 157 interventional ones that give a count, is one of 6 that started in 2026, is one of 27 with no phase, reaches primary completion later than 22 of the 45 other live ones, and was the 152nd registered.
3,972 studies on the registry are indexed under Alzheimer Disease; 932 are open to participants now.
Browse Alzheimer Disease studies →34 of the 174 studies in Alzheimer Disease with a site in Korea, Republic of are open now. Recruiting first, the newest first:
ReadyCure Inc. · Sites in Korea, Republic of
Ages 60–85
Eli Lilly and Company · Sites in Korea, Republic of, United States, Japan and 1 more country
Ages 55–85
CKD Bio Corporation · Sites in Korea, Republic of
Ages 55–85
Neumous Inc. · Sites in Korea, Republic of
Ages 50–85
Bristol-Myers Squibb · Sites in Korea, Republic of, United States, Argentina and 23 more countries
Ages 55–90
A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →
Of the 644 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 286 take healthy volunteers.
This study: 60 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
174 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 37 · Phase 3 65 · Phase 4 13
First in 2003; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is below the median of 70 across 3,024 interventional studies indexed under Alzheimer Disease.
Median enrollment 206 across the 157 interventional studies, 500 across the 17 observational. Of the 109 that completed or were terminated, 45 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
125 of 174 have an industry lead sponsor. The 10 most frequent:
NVP Healthcare is the lead sponsor of 22 studies on the registry; 2 are open to participants now.
NVP Healthcare has 1 study filed under Alzheimer Disease — fewer than ten, so there is no comparison to draw.
15 of the studies in Alzheimer Disease with a site in Korea, Republic of that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06585787Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | 2026-11-24 |
| NCT06126224Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyA Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2) | 2026-12-09 |
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT05980949Phase 3Karuna Therapeutics, Inc., a Bristol Myers Squibb companyOpen-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) | 2027-09-07 |
| NCT06402838Hoffmann-La RocheA Study to Evaluate the Safety and Biomarker Effects of RO7269162 in Participants at Risk for or at the Prodromal Stage of Alzheimer's Disease (AD) | 2026-11-19 |
Add all 15 to your calendar (.ics) → With an account.
Among the 174 studies in Alzheimer Disease with a site in Korea, Republic of, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this clinical trial is to exploratively evaluate the efficacy and safety of NVP -NK4146 in improving mild cognitive impairment (MCI) in patients with due to Alzheimer's disease (AD) compared to placebo
36-week, single-center, randomized, double-blind, parallel-design, placebo-controlled trial
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NVP-NK4146
Dietary Supplement: NVP-NK4146
NVP-NK4146 Placebo
Dietary Supplement: NVP-NK4146 Placebo
BID for 36 weeks orally
BID for 36 weeks orally
amyloid PET scan
Changes in brain amyloid measured by amyloid PET scan from baseline to 36 weeks
Time frame: baseline and 36 weeks
ADAS-Cog(Alzheimer's Disease Assessment Scale-Cognitive Subscale)13
Changes in ADAS-Cog 13 total score, memory score, and subscales from baseline to 36 weeks
Time frame: baseline and 36 weeks
CDR-SB(Clinical Dementia Rating-Sum of Boxes)
Changes in CDR-SB(Clinical Dementia Rating-Sum of Boxes) and CDR total score from baseline to 36 weeks
Time frame: baseline and 36 weeks
GDS (Global Deterioration Scale)
Change in GDS total score from baseline to 36 weeks
Time frame: baseline and 36 weeks
K-MMSE (the Korean Mini-Mental State Examination)
Change in K-MMSE total score from baseline to 36 weeks
Time frame: baseline and 36 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Sep 2027, 20 months after the start.
Of 77 industry-sponsored interventional studies with no phase under Alzheimer Disease, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 40. This study's planned 20 months is above that.
Counting every sponsor, half of 963 studies reached it within 29 months; a quarter within 15 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.